Actemra actpen 162 MG/0.9 ML 0.9ML
Ended Awarded
- Contract number
- SPE2DB26FAAS2
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,689
Award facts
- Contract value 100% obligated
- $29,689.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,689.19 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens. This non-set-aside award is a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX and valued at $999,999,999.00 through December 2026), which serves as the primary pharmaceutical supply vehicle for military healthcare programs worldwide. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 28, 2025.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, demonstrates substantial capability in meeting federal medical procurement requirements through its extensive portfolio of delivery orders with DLA and other military healthcare entities. The company's contract awards reflect consistent competitively-awarded, non-set-aside transactions involving firm fixed pricing across a wide spectrum of pharmaceutical products and medical supplies supporting Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. This specific delivery order for Actemra, a biologic immunosuppressant commonly used in rheumatologic conditions, contributes to AmerisourceBergen's critical role in maintaining pharmaceutical supply chains for military medical operations.
Quick answers
Who was awarded contract SPE2DB26FAAS2?
SPE2DB26FAAS2 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FAAS2 worth?
The government has obligated $29,689 on SPE2DB26FAAS2.
Is contract SPE2DB26FAAS2 an order under another contract?
Yes. SPE2DB26FAAS2 is a delivery order under SPE2DB22D3016, an indefinite delivery contract.
Was contract SPE2DB26FAAS2 competed?
The extent of competition for SPE2DB26FAAS2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award